SGMO Earnings

SGMO reported its FY2025Q4 earnings on 2026-03-16, showcasing a revenue of against an estimate of 35.00M, resulting in a 0% surprise. The EPS was 0, surpassing the expected 0.01 by 0%. The stock experienced a 0% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following SGMO's FY2025Q4 earnings announcement on 2026-03-16, the stock price moved by 0% on the day of the release. Over the subsequent five days, it saw a 0% change. Historically, SGMO's stock price tends to shift by an average of 4.3% in the 10 days leading up to earnings and -16.55% in the 10 days following, providing insight into potential market.

For 2025/Q4, analysts estimate SGMO's annual revenue to reach 40.25M, while the EPS is projected at -0.01. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between SGMO's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, SGMO's stock price typically moves by 4.3% in the 10 days before its earnings and -16.55% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of -0.01 and revenue of 40.25M.

The earnings call highlighted strong financial metrics, including a sufficient cash runway into 2026 and positive clinical data across multiple programs. While the Q&A revealed some uncertainties in partnership negotiations, the FDA's supportive stance on the Fabry disease program and ongoing interest in other platforms provide optimism. The call's overall tone was positive, with strong clinical results and financial health suggesting a likely stock price increase of 2% to 8% over the next two weeks.